Could a common antibiotic beat stubborn joint infections?
NCT ID NCT05902221
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial investigates whether adding the antibiotic rifampicin to standard treatment improves outcomes for people with prosthetic joint infections caused by Cutibacterium acnes bacteria. These infections are hard to treat because the bacteria form a protective biofilm. The study involves 235 adults with infected hip, knee, or shoulder replacements who will receive either standard antibiotics alone or standard antibiotics plus rifampicin for 12 weeks. Researchers will track treatment failures and side effects to see if the combination works better.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- rifampicin
- What this could lead to
- If adding rifampicin works, it could become a standard part of treatment for these stubborn joint infections, reducing the need for repeat surgeries.
- What could go wrong
- This is a phase 3 trial, but rifampicin may cause side effects like liver problems or drug interactions, and the infection might still return.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 235 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2024
- Expected to finish
-
May 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age: \> or =18 years old; * Monomicrobial, rifampicin susceptible Cutibacterium acnes late total knee arthroplasty (TKA) or hip arthroplasty (total, THA or hemiarthroplasty, HH) or shoulder arthroplasty (total, TSA or hemiarthroplasty, SH) infection treated surgically with single-stage or two-stage revision; * Isolation of C. acnes on two distinct per-operative samples collected during the single-stage or the two-stage revision * Based on the antimicrobial susceptibility test of the C. acnes and the medical history of the patient, the PJI can be treated with amoxicillin or moxifloxacin; * Women considered of childbearing potential (WOCBP) requires use of a highly effective contraceptive measure as intrauterine device (IUD), intrauterine hormone-releasing system (IUS), documented bilateral tubal occlusion, documented vasectomised partner, sexual abstinence. Contraception should be maintained during treatment and until the end of relevant systemic exposure. Exclusion Criteria: * Contraindication to Rifampicin (included ongoing treatment contraindicated with rifampicin) * Contraindication to Amoxicillin AND moxifloxacin (included ongoing treatment contraindicated with these medicines) * Empirical antibiotic treatment not administered during the 24 hours following revision surgery; * Inactive empirical antibiotic treatment following surgery according to the AST of the bacteria; * disease-modifying treatment incompatible with the inducer effect of rifampicin * Liver cirrhosis; * Pregnancy: a pregnancy blood test will be performed on all women of childbearing age. The results will be sent to the patient by the doctor of their choice; * Porphyria; * Renal insufficiency with GFR \< 30ml/min/1.73 m2 (CKD-EPI);
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cutibacterium acnes prosthetic joint infection are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
13 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
AP-HM
NOT_YET_RECRUITINGMarseille, France
-
CH Annecy Genevois
RECRUITINGAnnecy, France
-
CHRU Tours
RECRUITINGTours, France
-
CHU Toulouse
RECRUITINGToulouse, France
-
CHU de BORDEAUX
RECRUITINGBordeaux, France
-
CHU de MONTPELLIER
RECRUITINGMontpellier, France
-
CHU de NICE
RECRUITINGNice, 06200, France
-
CHU de Nantes
RECRUITINGNantes, France
-
CHU de Rennes
RECRUITINGRennes, France
-
Ch Tourcoing
RECRUITINGTourcoing, France
-
Dianonesses croix saint simon
RECRUITINGParis, France
-
HCL
RECRUITINGLyon, France
-
Hôpital Ambroise Paré
RECRUITINGBoulogne, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.